Shionogi & Co. (SGIOY)
(Delayed Data from OTC)
$11.50 USD
+0.10 (0.83%)
Updated Aug 23, 2024 03:56 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
SGIOY 11.50 +0.10(0.83%)
Will SGIOY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGIOY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGIOY
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Upgraded to Buy: Here's Why
SGIOY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SGIOY
AMR Update - Mid-2024
Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript
ViiV's Dovato as effective as Gilead's Biktarvy for HIV but with less weight gain
Viiv's Dovato as effective as Gilead' Biktarvy for HIV but with less weight gain
GSK announces promising trial data for ViiV Healthcare HIV drugs